Clinical Trial: A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885293) titled 'A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP' on Oct. 12.

Brief Summary: This trial is a multicenter, open label, randomized phase III clinical study that evaluates the efficacy of oral HS-10382 versus investigator selected TKIs (imatinib, nilotinib, dasatinib, and flumatinib) in newly diagnosed Ph+CML-CP adult participants. The TKI drug chosen by the investigators is the FDA/NMPA approved CML-CP first-line treatment drug: imatinib or nilotinib or dasatinib or flumatinib.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Chronic Myeloid Leukemia

Interve...